Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The third-generation HPV vaccine is a **preclinical multivalent chimeric epitope HPV vaccine** being developed by **Xiamen Innovax Biotech** for prevention of **HPV-related diseases**, including **cervical cancer**. The candidate was designed using **structural vaccinology** principles to create a broad-spectrum, \"one-against-multi\" immunogen that incorporates neutralizing epitopes from multiple HPV types into chimeric constructs rather than using separate full virus-like particles for each type. It is produced on Innovax's proprietary **Escherichia coli expression platform** and is intended to elicit neutralizing antibody responses against HPV capsid epitopes with the goal of broad preventive efficacy across HPV-associated disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on third-generation HPV vaccine.